Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Diverse coalition urges California Governor to sign bill to provide health coverage for smoking cessation treatments

A large and unusually diverse of group of interests have come together to urge Governor Schwarzenegger to sign a key health related measure, Senate Bill 220 (Yee, D-San Francisco), which would provide health coverage of smoking cessation treatments and services.

18 Sep 2010

Research Roundup: Assessing physician quality; Community health centers' future; Why doctors take gifts; Access to HIV treatment

Archives of Internal Medicine: Associations Between Physician Characteristics And Quality Of Care - Since "most patients do not have access to physician quality measures," they are often encouraged to use public information such as malpractice claims and board certification status to chose a doctor, according to this report that used 2004-2005 insurance claims from about 10,000 Massachusetts physicians for more than 1.13 million adults.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Abiomed to provide updates on USpella registry, Impella case reviews at CRF annual TCT meeting

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced its schedule of events at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from September 21 - 25, at the Washington Convention Center in Washington, DC.

17 Sep 2010

FDA approves expanded indication for Boston Scientific's CRT-Ds

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS® CRT-D. The exclusive expanded indication is effective immediately and makes Boston Scientific CRT-Ds the only devices approved by the FDA for patients in all New York Heart Association (NYHA) classes of heart failure.

17 Sep 2010

FDA approves CRT-D device to treat heart failure patients

The U.S. Food and Drug Administration today approved a new indication for three cardiac resynchronization therapy defibrillators (CRT-D) used to treat certain heart failure patients.

17 Sep 2010

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

Roche Diagnostics announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes.

From Roche Sequencing and Life Science 17 Sep 2010

HFSA to discuss 'Designing the Medical Home for Heart Failure Patients' at Scientific Meeting

The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion titled "Designing the Medical Home for Heart Failure Patients." Contributors Dr. Mary Norine Walsh and Dr. Larry A. Allen will describe treatment and care strategies in the medical home model and how they impact both patients and caregivers.

16 Sep 2010

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

16 Sep 2010

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT and the weight loss medication sibutramine (sold as Meridia® in the United States).

16 Sep 2010

New approach to evaluate risk of cardiovascular disease

A new approach to evaluating a person's risk of cardiovascular disease, stroke, high blood pressure, or heart failure is reported this month in the International Journal of Data Mining, Modelling and Management. The technique uses fuzzy logic to teach a neural network computer program to analyze patient data and spot correlations that can be translated into a risk factor for an individual.

16 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

Researchers recommend mechanism to identify hypertrophic cardiomyopathy

An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages. So says a task force of cardiologists and cardiac biologists, headed by Thomas L. Force, M.D., James C. Wilson Professor of Medicine at Thomas Jefferson University, in the September 14th online edition of the journal Circulation.

15 Sep 2010

Heart patients with Type D personality at higher risk of future cardiovascular problems

Heart patients with the "distressed" (Type D) personality profile may face a higher risk of future cardiovascular problems, according to a summary article published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Long-term stenting of aortic coarctation yields 77% success rate

Researchers from the Congenital Cardiovascular Interventional Study Consortium (CCISC) who evaluated the intermediate and long-term results of stent implantation for aortic coarctation found that cumulative intermediate success was 86%, and cumulative long-term success was 77%. Results of this study appear in the October issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

14 Sep 2010

Public reporting of quality information helps consumers choose the right physician: Study

When looking for a new physician, patients are often encouraged to select those who are board certified or who have not made payments on malpractice claims. Yet these characteristics are not always a good predictor of which physicians will provide the highest quality medical care, according to a new study from the RAND Corporation, a nonprofit research organization, and the University of Pittsburgh School of Medicine.

14 Sep 2010

Study shows Americans with muscular dystrophy live longer than African-Americans

A new study shows that white men and boys are living longer with muscular dystrophy due to technological advances in recent years, but that the lives of African-American men and boys with muscular dystrophy have not been extended at the same rate. The research will be published in the September 14, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

14 Sep 2010

Heart Failure News and Research

Further Reading

Diverse coalition urges California Governor to sign bill to provide health coverage for smoking cessation treatments

Research Roundup: Assessing physician quality; Community health centers' future; Why doctors take gifts; Access to HIV treatment

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Abiomed to provide updates on USpella registry, Impella case reviews at CRF annual TCT meeting

FDA approves expanded indication for Boston Scientific's CRT-Ds

FDA approves CRT-D device to treat heart failure patients

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

HFSA to discuss 'Designing the Medical Home for Heart Failure Patients' at Scientific Meeting

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

New approach to evaluate risk of cardiovascular disease

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Study finds GRK2 molecule promotes cell death after heart attack

Researchers recommend mechanism to identify hypertrophic cardiomyopathy

Heart patients with Type D personality at higher risk of future cardiovascular problems

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

FDA approves Krystexxa drug to treat gout

Long-term stenting of aortic coarctation yields 77% success rate

Public reporting of quality information helps consumers choose the right physician: Study

Study shows Americans with muscular dystrophy live longer than African-Americans

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News